Kevin C. Entzminger

Engineering a pH-sensitive humanized infliximab with improved potency and developability using STEM™

Background Tumor necrosis factor-α inhibitors such as infliximab and adalimumab have transformed autoimmune disease treatment; however, infliximab is a mouse-human chimeric antibody that remains immunogenic, is associated with self-association/aggregation liability, and requires prolonged intravenous administration. We...